Doxorubicin Hydrochloride Injection, Suspension, Liposomal
Product Images NDC 46708-810

This is a detailed description of a pharmaceutical product from Alembic Pharmaceuticals Limited - a Doxorubicin Hydrochloride Liposome Injection with a concentration of 20mg per 10mL (2mg/mL). It is a liposomal formulation meant for intravenous infusion only after dilution. The product needs to be refrigerated at 2 to 8°C and should not be frozen. The injection contains components such as pegylated liposome carriers, cholesterol, hydrogenated soy phosphatidylcholine, and PEG-DSPE. Additionally, it includes ammonium sulfate, hydrochloric acid, and sucrose. It is recommended to use 5% Dextrose injection, USP for dilution. The dosage should be as per the prescribing information provided.*

This is a pharmaceutical product labeled with NDC (National Drug Code) 46708-810-10 for DOXOrubicin Hydrochloride Liposome Injection in a 10 mL Single-Dose Vial with 20 mg strength per 10 mL (2 mg/mL). The medication is for intravenous infusion only after dilution. It is emphasized that it is a liposomal formulation and not to be substituted for Doxorubicin. The product is manufactured by Alembic Pharmaceuticals Limited in Gujarat, India. The lot number and expiration date are not provided in the text.*

This text refers to a medication called DOXOrubicin Hydrochloride Liposome Injection, which is a cytotoxic drug for intravenous infusion after dilution. The formulation contains various components like doxorubicin hydrochloride, pegylated liposome carriers, and other ingredients. It is advised to refrigerate the product at 2° to 8°C and not freeze it. The medication comes in a 25 mL single-dose vial and should be administered with 5% Dextrose Injection, USP. It is essential to follow prescribing information and not substitute it with other forms of doxorubicin hydrochloride.*

This text provides information on a medication called DOXOrubicin Hydrochloride Liposome Injection. The injection comes in a 50 mg/25 mL (2mg/ml) single-dose vial for intravenous infusion only after dilution. It is recommended to use 5% Dextrose Injection, USP when diluting the medication and to discard any unused portion. The storage instructions indicate refrigeration at 2°C to 8°C (36°F to 46°F). It is a cytotoxic medication that should not be substituted with regular DOXOrubicin Hydrochloride. The manufacturer is Alembic Pharmaceuticals Limited and the prescription is required for this medication. Detailed prescribing information, including recommended dosage, should be consulted before use.*

This is a statistical analysis showing the comparison of two treatments: Doxorubicin HCl + Bortezomib and Bortezomib alone. The data includes a p-value of less than 0.0001 indicating statistical significance. The hazard ratio and 95% confidence interval are reported as 0.5 (0.43, 0.71), favoring the Doxorubicin HCl + Bortezomib treatment. The table also contains information on the number of subjects at risk over time in months for each treatment group.*

This text mentions a "MPEG-DSPE coating" that contains an "Aqueous core with entrapped doxorubicin HCI" and a "Liposomal bilayer." This suggests a pharmaceutical formulation involving lipid nanoparticles with a specialized coating for drug delivery purposes.*